Yesafili is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Yesafili is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameYesafili
Authorized genericaflibercept-jbvf
Regular genericaflibercept-jbvf
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Yesafili?
The original
–
–

Brand nameThe maker’s card

My Biocon Biologics Co-Pay Card

Savings card from Biocon Biologics

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

Sign up on yesafili.com 

Or call 1-833-612-4626.

In the maker’s words

“My Biocon Biologics Co-Pay Card patients may pay as little as: ◦ $0 out-of-pocket for each dose or prescription of the My Biocon Biologics product.”

From the maker’s offer on yesafili.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Yesafili itself, from the same company, sold without the brand name, and usually for less. For now Yesafili is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Yesafili is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)

Source: the FDA label for Yesafili (Biocon Biologics Inc.), July 28, 2026. Full label on DailyMed 

Good to know